CONSOLIDATED BALANCE SHEETS (UNAUDITED) - USD ($) $ in Millions	Sep. 30, 2022	Dec. 31, 2021
Current Assets:
Cash and cash equivalents	$ 7,734	$ 13,979
Marketable debt securities	1,293	2,987
Receivables	9,613	9,369
Inventories	2,074	2,095
Other current assets	6,082	4,832
Total Current Assets	26,796	33,262
Property, plant and equipment	6,035	6,049
Goodwill	21,112	20,502
Other intangible assets	38,179	42,527
Deferred income taxes	1,329	1,439
Other non-current assets	4,745	5,535
Total Assets	98,196	109,314
Current Liabilities:
Short-term debt obligations	2,132	4,948
Accounts payable	2,595	2,949
Other current liabilities	14,203	13,971
Total Current Liabilities	18,930	21,868
Deferred income taxes	2,881	4,501
Long-term debt	36,966	39,605
Other non-current liabilities	6,685	7,334
Total Liabilities	65,462	73,308
Commitments and contingencies
Bristol-Myers Squibb Company Shareholders’ Equity:
Preferred stock	0	0
Common stock	292	292
Capital in excess of par value of stock	44,956	44,361
Accumulated other comprehensive loss	(841)	(1,268)
Retained earnings	24,675	23,820
Less cost of treasury stock	(36,411)	(31,259)
Total Bristol-Myers Squibb Company Shareholders’ Equity	32,671	35,946
Noncontrolling interest	63	60
Total Equity	32,734	36,006
Total Liabilities and Equity	$ 98,196	$ 109,314